AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall … Read more
AngioDynamics Inc (ANGO) - Net Assets
Latest net assets as of November 2025: $176.33 Million USD
Based on the latest financial reports, AngioDynamics Inc (ANGO) has net assets worth $176.33 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($269.68 Million) and total liabilities ($93.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $176.33 Million |
| % of Total Assets | 65.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -58.36% |
| 10-Year Change | -63.91% |
| Growth Volatility | 499.6 |
AngioDynamics Inc - Net Assets Trend (2002–2025)
This chart illustrates how AngioDynamics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AngioDynamics Inc (2002–2025)
The table below shows the annual net assets of AngioDynamics Inc from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-05-31 | $182.97 Million | -11.00% |
| 2024-05-31 | $205.59 Million | -45.65% |
| 2023-05-31 | $378.30 Million | -10.88% |
| 2022-05-31 | $424.49 Million | -3.41% |
| 2021-05-31 | $439.46 Million | -3.60% |
| 2020-05-31 | $455.87 Million | -25.85% |
| 2019-05-31 | $614.82 Million | +13.31% |
| 2018-05-31 | $542.60 Million | +4.95% |
| 2017-05-31 | $517.03 Million | +1.97% |
| 2016-05-31 | $507.03 Million | -6.97% |
| 2015-05-31 | $545.02 Million | +1.33% |
| 2014-05-31 | $537.89 Million | +2.10% |
| 2013-05-31 | $526.83 Million | +0.66% |
| 2012-05-31 | $523.39 Million | +28.99% |
| 2011-05-31 | $405.75 Million | +3.68% |
| 2010-05-31 | $391.35 Million | +5.15% |
| 2009-05-31 | $372.19 Million | +4.63% |
| 2008-05-31 | $355.71 Million | +5.88% |
| 2007-05-31 | $335.96 Million | +172.17% |
| 2006-05-31 | $123.44 Million | +151.35% |
| 2005-05-31 | $49.11 Million | +31.90% |
| 2004-05-31 | $37.23 Million | +2402.15% |
| 2003-05-31 | $1.49 Million | +604.41% |
| 2002-05-31 | $-295.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to AngioDynamics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41706800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $385.00K | 0.21% |
| Other Comprehensive Income | $-2.02 Million | -1.11% |
| Other Components | $613.80 Million | 335.47% |
| Total Equity | $182.97 Million | 100.00% |
AngioDynamics Inc Competitors by Market Cap
The table below lists competitors of AngioDynamics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SanBio Company Limited
OTCGREY:SNBIF
|
$354.45 Million |
|
Hengxin Mobile Business
SHE:300081
|
$354.56 Million |
|
RWS Holdings plc
PINK:RWSPF
|
$354.56 Million |
|
Hootech Inc.
SHE:301026
|
$354.60 Million |
|
Natural Grocers by Vitamin Cottage Inc
NYSE:NGVC
|
$354.38 Million |
|
Tremor International Ltd
PINK:TTTPF
|
$354.16 Million |
|
Intrum AB (publ)
PINK:ITJTY
|
$354.15 Million |
|
Depo Auto Parts Industrial Co Ltd
TW:6605
|
$354.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AngioDynamics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 205,586,000 to 182,970,000, a change of -22,616,000 (-11.0%).
- Net loss of 33,993,000 reduced equity.
- Share repurchases of 1,670,000 reduced equity.
- Other comprehensive income increased equity by 2,342,000.
- Other factors increased equity by 10,705,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.99 Million | -18.58% |
| Share Repurchases | $1.67 Million | -0.91% |
| Other Comprehensive Income | $2.34 Million | +1.28% |
| Other Changes | $10.71 Million | +5.85% |
| Total Change | $- | -11.00% |
Book Value vs Market Value Analysis
This analysis compares AngioDynamics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-05-31 | $-0.03 | $10.71 | x |
| 2003-05-31 | $0.16 | $10.71 | x |
| 2004-05-31 | $3.78 | $10.71 | x |
| 2005-05-31 | $3.98 | $10.71 | x |
| 2006-05-31 | $9.52 | $10.71 | x |
| 2007-05-31 | $18.22 | $10.71 | x |
| 2008-05-31 | $14.61 | $10.71 | x |
| 2009-05-31 | $15.18 | $10.71 | x |
| 2010-05-31 | $15.79 | $10.71 | x |
| 2011-05-31 | $16.14 | $10.71 | x |
| 2012-05-31 | $20.62 | $10.71 | x |
| 2013-05-31 | $15.13 | $10.71 | x |
| 2014-05-31 | $15.18 | $10.71 | x |
| 2015-05-31 | $15.27 | $10.71 | x |
| 2016-05-31 | $14.02 | $10.71 | x |
| 2017-05-31 | $13.99 | $10.71 | x |
| 2018-05-31 | $14.45 | $10.71 | x |
| 2019-05-31 | $16.40 | $10.71 | x |
| 2020-05-31 | $12.01 | $10.71 | x |
| 2021-05-31 | $11.46 | $10.71 | x |
| 2022-05-31 | $10.88 | $10.71 | x |
| 2023-05-31 | $9.58 | $10.71 | x |
| 2024-05-31 | $5.12 | $10.71 | x |
| 2025-05-31 | $4.46 | $10.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AngioDynamics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.62%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 1.53x
- Recent ROE (-18.58%) is below the historical average (-2.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 3.27% | 1.50x | 0.00x | $1.04 Million |
| 2003 | 79.70% | 3.09% | 1.42x | 18.18x | $1.04 Million |
| 2004 | 8.44% | 6.41% | 0.99x | 1.34x | $-580.20K |
| 2005 | 9.26% | 7.54% | 1.01x | 1.22x | $-363.00K |
| 2006 | 5.56% | 8.75% | 0.57x | 1.11x | $-5.48 Million |
| 2007 | -2.72% | -8.13% | 0.29x | 1.14x | $-42.72 Million |
| 2008 | 3.06% | 6.54% | 0.41x | 1.15x | $-24.68 Million |
| 2009 | 2.67% | 5.09% | 0.48x | 1.10x | $-27.29 Million |
| 2010 | 3.15% | 5.70% | 0.51x | 1.08x | $-26.82 Million |
| 2011 | 2.00% | 3.76% | 0.49x | 1.08x | $-32.46 Million |
| 2012 | -0.99% | -2.34% | 0.31x | 1.39x | $-57.52 Million |
| 2013 | -0.23% | -0.35% | 0.43x | 1.50x | $-53.89 Million |
| 2014 | 0.44% | 0.66% | 0.44x | 1.49x | $-51.44 Million |
| 2015 | -0.62% | -0.95% | 0.46x | 1.42x | $-57.89 Million |
| 2016 | -8.60% | -12.32% | 0.49x | 1.44x | $-94.29 Million |
| 2017 | -1.36% | -2.02% | 0.49x | 1.37x | $-58.75 Million |
| 2018 | 3.01% | 4.74% | 0.49x | 1.30x | $-37.92 Million |
| 2019 | 9.98% | 17.06% | 0.43x | 1.36x | $-141.50K |
| 2020 | -36.59% | -63.14% | 0.44x | 1.31x | $-212.37 Million |
| 2021 | -7.18% | -10.84% | 0.52x | 1.28x | $-75.49 Million |
| 2022 | -6.25% | -8.40% | 0.57x | 1.30x | $-69.00 Million |
| 2023 | -13.86% | -15.48% | 0.64x | 1.41x | $-90.27 Million |
| 2024 | -89.67% | -60.66% | 0.96x | 1.55x | $-204.91 Million |
| 2025 | -18.58% | -11.62% | 1.04x | 1.53x | $-52.29 Million |
Industry Comparison
This section compares AngioDynamics Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,942,172,491
- Average return on equity (ROE) among peers: -36.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AngioDynamics Inc (ANGO) | $176.33 Million | 0.00% | 0.53x | $354.40 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |